[go: up one dir, main page]

EP3952840A4 - PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS - Google Patents

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS Download PDF

Info

Publication number
EP3952840A4
EP3952840A4 EP19924315.5A EP19924315A EP3952840A4 EP 3952840 A4 EP3952840 A4 EP 3952840A4 EP 19924315 A EP19924315 A EP 19924315A EP 3952840 A4 EP3952840 A4 EP 3952840A4
Authority
EP
European Patent Office
Prior art keywords
treatment
methods
pharmaceutical compositions
cognitive disorders
mental behavior
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19924315.5A
Other languages
German (de)
French (fr)
Other versions
EP3952840A1 (en
Inventor
Jianmin Wang
Geping Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LA Pharmatech Inc
Original Assignee
LA Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LA Pharmatech Inc filed Critical LA Pharmatech Inc
Publication of EP3952840A1 publication Critical patent/EP3952840A1/en
Publication of EP3952840A4 publication Critical patent/EP3952840A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19924315.5A 2019-04-12 2019-04-12 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS Pending EP3952840A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/027293 WO2020209872A1 (en) 2019-04-12 2019-04-12 Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Publications (2)

Publication Number Publication Date
EP3952840A1 EP3952840A1 (en) 2022-02-16
EP3952840A4 true EP3952840A4 (en) 2022-11-23

Family

ID=72751206

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19924315.5A Pending EP3952840A4 (en) 2019-04-12 2019-04-12 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS

Country Status (6)

Country Link
EP (1) EP3952840A4 (en)
JP (1) JP7365426B2 (en)
CN (1) CN113939276A (en)
AU (1) AU2019445048A1 (en)
CA (1) CA3136633A1 (en)
WO (1) WO2020209872A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
WO2020222799A1 (en) * 2019-04-30 2020-11-05 La Pharma Tech Inc. A method of treating mental, behavioral, cognitive disorders
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0517891A (en) * 2004-11-24 2008-10-21 Medpointe Healthcare Inc compositions comprising azelastine and methods of use thereof
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2018081508A1 (en) * 2016-10-28 2018-05-03 Chase Pharmaceutical Corporation Memantine combinations and use
JP7198575B2 (en) * 2017-07-11 2023-01-04 キョーリンリメディオ株式会社 Orally disintegrating tablet containing memantine hydrochloride

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 *
TARIOT PIERRE N ET AL: "MEMANTINE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER DISEASE ALREADY RECEIVING DONEPEZIL. A RANDOMIZED CONTROLLED TRIAL", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 291, no. 3, 21 January 2004 (2004-01-21), pages 317 - 324, XP009075923, ISSN: 0098-7484, DOI: 10.1001/JAMA.291.3.317 *

Also Published As

Publication number Publication date
WO2020209872A1 (en) 2020-10-15
JP7365426B2 (en) 2023-10-19
AU2019445048A1 (en) 2021-12-02
JP2022535644A (en) 2022-08-10
CA3136633A1 (en) 2020-10-15
EP3952840A1 (en) 2022-02-16
CN113939276A (en) 2022-01-14

Similar Documents

Publication Publication Date Title
EP3952840A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS
EP3931189A4 (en) AZEPINO-INDOLES AND OTHER HETEROCYCLIES FOR THE TREATMENT OF BRAIN DISEASES
EP3908270A4 (en) COMBINATION OF DEXTROMETHORPHANE AND BUPROPION FOR THE TREATMENT OF DEPRESSION
EP3490603A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF MASP-3 FOR TREATMENT OF VARIOUS DISEASES AND DISORDERS
EP3826666A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NRP2-ASSOCIATED DISEASES
EP3858353A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NITM AND ITS PHARMACEUTICAL USE
EP3507371A4 (en) PROCEDURES AND COMPOSITIONS AND TREATMENT OF DISEASES AND DISORDERS OF THE NERVOUS SYSTEM
EP3969597A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATPASE-MEDIATED DISEASES
EP3621593A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT OF CARDIAC DISEASES
EP3917539A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS
EP3581175A4 (en) MEDICINAL DELIVERY FORMULATION FOR THE TREATMENT OF MENTAL DISEASES OR CENTRAL NERVOUS SYSTEM DISORDERS
EP4008718C0 (en) HETEROARYLAMIDOPYRIDINOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES
EP3972691A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DRUG OVERDOSE
EP3689875A4 (en) USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS, AND COMPOSITIONS THEREOF, FOR THE TREATMENT OF PRC2-MEDIATED DISEASES
EP3813793A4 (en) COMPOSITION FOR THE TREATMENT OF OCULAR HYPEREMIA AND METHODS FOR TREATMENT OF OCULAR HYPEREMIA THEREFORE
EP3816285A4 (en) GENE SPECIFIC DOUBLE STRAND AMPHIREGULINE OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION AND TREATMENT OF FIBROTIC DISEASES AND RESPIRATORY DISEASES THEREOF
EP3856147A4 (en) METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF BONE DISEASES
EP3838898A4 (en) ISOINDOLIN-1-ON-DERIVATIVE, METHOD FOR ITS MANUFACTURING AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER
EP3558335A4 (en) CASPASE-1 INHIBITION AND ITS USE FOR THE PREVENTION AND TREATMENT OF NEUROLOGICAL DISEASES
EP4058017A4 (en) MEDICINAL FORMULATIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
EP3488850A4 (en) INNOVATIVE USE OF GZD824 AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF DISEASES
EP3636281A4 (en) METHOD OF TREATMENT OF DEPRESSION AND PHARMACEUTICAL COMPOSITION
EP3801483A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HORMONAL DISEASES OR DISORDERS
EP3730144A4 (en) AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM
EP3600324A4 (en) MEDICINAL PRODUCTS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221024

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20221018BHEP

Ipc: A61K 47/00 20060101ALI20221018BHEP

Ipc: A61K 31/495 20060101ALI20221018BHEP

Ipc: A61K 31/55 20060101ALI20221018BHEP

Ipc: A61K 31/13 20060101ALI20221018BHEP

Ipc: A61K 9/48 20060101ALI20221018BHEP

Ipc: A61K 9/20 20060101ALI20221018BHEP

Ipc: A61K 9/14 20060101ALI20221018BHEP

Ipc: A61K 9/10 20060101ALI20221018BHEP

Ipc: A61K 9/08 20060101AFI20221018BHEP